GlobeNewswire: BioStem Technologies, Inc. Contains the last 10 of 69 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T08:03:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/09/06/2738692/0/en/BioStem-Awarded-a-Spot-on-ECAT-DAPA-and-FSS-Contract-Vehicles-Through-SDVOSB-Lovell.html?f=22&fvtc=4&fvtv=40559BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell2023-09-06T16:00:00Z<![CDATA[PENSACOLA, FL, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lovell® Government Services (‘Lovell’) and BioStem Technologies (POMPANO BEACH, FL, ‘BioStem’) announced today that they have successfully listed BioStem on key government contract vehicles. Government Customers can now find BioStem’s portfolio of placental-based tissue allografts for advanced wound care on the Department of Defense’s Distribution and Pricing Agreement (DAPA), the Department of Veterans Affairs Federal Supply Schedule (FSS), and the Defense Logistics Agency’s ECAT system. This listing was made possible by BioStem’s Service-Disabled Veteran-Owned Small Business (SDVOSB) exclusive partner, Lovell Government Services.]]>Lovell® Government ServicesBioStem Technologieshttps://www.globenewswire.com/news-release/2023/03/23/2633015/0/en/BioStem-Technologies-Commends-OIG-s-Recommendation-for-CMS-to-Address-ASP-Reporting-Requirements-for-Skin-Substitute-Products.html?f=22&fvtc=4&fvtv=40559BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products2023-03-23T11:30:00Z<![CDATA[POMPANO BEACH, FLORIDA., March 23, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies (“BioStem” or the “Company”) (OTCQB: BSEM), a leading provider of innovative regenerative medicine solutions, is commending the U.S. Department of Health and Human Services Office of Inspector General's (HHS OIG) recent recommendation for the Centers for Medicare and Medicaid Services (CMS) to quickly address issues associated with Average Sales Price (ASP) reporting requirements for skin substitute products.]]>https://www.globenewswire.com/news-release/2023/03/07/2621924/0/en/BioStem-Technologies-to-Acquire-Majority-of-Assets-of-Auxocell-Laboratories-Inc.html?f=22&fvtc=4&fvtv=40559BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.2023-03-07T12:30:00Z<![CDATA[POMPANO BEACH, FLORIDA., March 07, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (“BioStem” or the “Company”) (OTCQB: BSEM), announced today that it has entered into an Agreement to acquire the majority of the assets of Auxocell Laboratories, Inc. ("Auxocell”), a leading solid tissue processing equipment manufacturer.]]>https://www.globenewswire.com/news-release/2023/02/14/2607673/0/en/BioStem-Technologies-Enters-Into-a-Share-Exchange-Agreement.html?f=22&fvtc=4&fvtv=40559BioStem Technologies Enters Into a Share Exchange Agreement2023-02-14T13:55:00Z<![CDATA[The Company will Acquire Back 10% of Issued and Outstanding Shares of its Non-Wholly Owned Subsidiary and Manufacturing Division]]>https://www.globenewswire.com/news-release/2023/02/01/2599330/0/en/BioStem-Technologies-Poised-for-Growth-with-Two-New-Hires-Michael-Sylvester-Joins-as-Vice-President-of-Sales-Neal-Bhattacharya-as-Vice-President-of-Marketing.html?f=22&fvtc=4&fvtv=40559BioStem Technologies Poised for Growth with Two New Hires: Michael Sylvester Joins as Vice President of Sales, Neal Bhattacharya as Vice President of Marketing2023-02-01T12:30:00Z<![CDATA[POMPANO BEACH, FLORIDA., Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (“BioStem” or the “Company) (OTCQB: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived tissue allografts for advanced wound care, today announced the appointment of Michael Sylvester as Vice President of Sales and Neal Bhattcharya as Vice President of Marketing.]]>https://www.globenewswire.com/news-release/2023/01/24/2594083/0/en/Center-for-Medicare-Services-Established-National-Pricing-of-VENDAJETM-in-All-MAC-regions.html?f=22&fvtc=4&fvtv=40559Center for Medicare Services Established National Pricing of VENDAJETM in All MAC regions2023-01-24T12:30:00Z<![CDATA[Pricing Provides VENDAJETM Reimbursement in All MAC Regions]]>https://www.globenewswire.com/news-release/2022/12/16/2575386/0/en/BioStem-Technologies-Announces-Up-Listing-to-the-OTCQB-Venture-Market.html?f=22&fvtc=4&fvtv=40559BioStem Technologies Announces Up-Listing to the OTCQB Venture Market2022-12-16T12:30:00Z<![CDATA[POMPANO BEACH, FLORIDA., Dec. 16, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTCQB: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, is pleased to announce that its common shares have been successfully up-listed from the OTC Pink Sheet Open Market to the OTCQB Venture Market (the “OTCQB”) by the OTC Markets Group Inc. (“OTC Markets”). The Company’s common shares will begin trading on the OTCQB under the symbol “BSEM” as of the opening of market on December 16, 2022.]]>https://www.globenewswire.com/news-release/2022/12/14/2573565/0/en/BioStem-Technologies-Announces-Partnership-with-Kill-Cliff-FC.html?f=22&fvtc=4&fvtv=40559BioStem Technologies Announces Partnership with Kill Cliff FC2022-12-14T12:30:00Z<![CDATA[Kill Cliff FC is One of the world’s largest MMA Training Centers with More Than 80 Professional Fighters]]>https://www.globenewswire.com/news-release/2022/11/15/2556672/0/en/BioStem-Technologies-Reports-Third-Quarter-2022-Operating-and-Financial-Results.html?f=22&fvtc=4&fvtv=40559BioStem Technologies Reports Third Quarter 2022 Operating and Financial Results2022-11-15T21:05:00Z<![CDATA[Company to Host a Conference Call and Webcast on November 15, 2022, at 4:30 pm EDT]]>https://www.globenewswire.com/news-release/2022/11/15/2556007/0/en/BioStem-Technologies-to-Host-Third-Quarter-Financial-Results-and-Corporate-Update-Conference-Call.html?f=22&fvtc=4&fvtv=40559BioStem Technologies to Host Third Quarter Financial Results and Corporate Update Conference Call2022-11-15T12:30:00Z<![CDATA[POMPANO BEACH, FLORIDA., Nov. 15, 2022 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, today announced it will host a conference call to discuss financial results for the quarter ended September 30, 2022 and provide a corporate update on Tuesday, November 15, 2022, at 4:30 pm EST.]]>